Image credit: Nushin Rashidian

CBD’s Potential for Reproductive Harms Among “Big Reasons” Behind FDA’s Punt on Rules

The FDA is seeking a “harm reduction framework” as it works with Congress on a path for CBD, according to the agency’s Cannabis Product Committee lead.

Congress, Newsletter

In Congress, Republicans Swing Against Cannabis Rescheduling

An excerpt from the Cannabis Wire Daily newsletter.

New York

Cannabis Loyalty Programs, Discounts Could Soon Come to New York’s Legal Shops

Regulators proposed new rules to open the door to billboards, discounts, and loyalty programs – which have already shown up at some shops.